DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

0090-9556/04/3204-455-459$20.00
DMD 32:455-459, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martineau, I.
Right arrow Articles by Bélanger, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martineau, I.
Right arrow Articles by Bélanger, A.

AMINO ACID RESIDUE ILE211 IS ESSENTIAL FOR THE ENZYMATIC ACTIVITY OF HUMAN UDP-GLUCURONOSYLTRANSFERASE 1A10 (UGT1A10)

Isabelle Martineau, André Tchernof, and Alain Bélanger

Oncology and Molecular Endocrinology Research Center, Laval University Medical Research Center (CHUL) and Laval University, Quebec, Canada

Conjugation of exogenous and endogenous compounds by uridine diphosphoglucuronosyltransferases (UGTs) is a pathway catalyzing the transfer of a glucuronic acid molecule from UDP glucuronic acid to lipophilic aglycones, which become more polar and more easily excretable in the bile or urine. UGTs are divided into two major families, UGT1 and UGT2. The isoform UGT1A10, along with UGT1A7 and UGT1A8, is expressed exclusively in extrahepatic tissues, notably in the gastrointestinal tract. Here, we report the isolation of a mutant clone of the human UGT1A10, at position 211 of the protein, where a threonine residue replaces an isoleucine residue (allele Thr211). Because the isoleucine is conserved among many UGT1A isoforms, we proceeded to the analysis of the activity of the wild-type UGT1A10 (T211I) and compared it with that of the variant enzyme (I211T*). In vitro assays with microsomal extracts from stably expressing human embryonic kidney 293 (HEK293) cells showed that the mutant enzyme lost all detectable activity toward major substrates, which demonstrate that the residue isoleucine at position 211 is essential for UGT1A10 activity. Mutant UGT1A10 (I211T*) also lost all detectable activity toward mycophenolic acid. Genomic DNA from 103 unrelated individuals was sequenced for this mutation, and two heterozygous genotypes were detected for this mutation (frequency: 2 per 100 individuals). Because UGT1A10 appears to be expressed in all gastrointestinal tissues and is active toward a wide range of substrates, lack of activity of this isoform may have an impact on individual glucuronidation efficiency.

Address correspondence to: Dr. Alain Bélanger, Oncology and Molecular Endocrinology, CHUL Research Center, 2705 Laurier Boulevard, Quebec, Quebec G1V 4G2, Canada. E-mail: Alain.Belanger{at}crchul.ulaval.ca




This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
T. Kubota, B. C. Lewis, D. J. Elliot, P. I. Mackenzie, and J. O. Miners
Critical Roles of Residues 36 and 40 in the Phenol and Tertiary Amine Aglycone Substrate Selectivities of UDP-Glucuronosyltransferases 1A3 and 1A4
Mol. Pharmacol., October 1, 2007; 72(4): 1054 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. K. Basu, L. Kole, S. Kubota, and I. S. Owens
RESPONSE TO THE LETTER TO THE EDITOR BY DRS. N. PICARD AND P. MARQUET REGARDING A PUBLICATION: BASU ET AL., DRUG METABOLISM AND DISPOSITION 32: 768-773 (2004)
Drug Metab. Dispos., December 1, 2004; 32(12): 1525 - 1525.
[Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.